Phosphodiesterase type 5, usually called PDE5, is an enzyme whose main job is to break down a signaling molecule called cyclic GMP (cGMP) in smooth muscle cells. When PDE5 inhibitors block that breakdown, cGMP accumulates, blood vessels relax, and blood flow increases. That single mechanism explains why drugs like sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) treat conditions as different as erectile dysfunction and pulmonary hypertension. But the biology behind that one-sentence summary is richer than most people realize, and it shapes everything from why these drugs cannot be mixed with certain heart medications to why researchers are now testing them against stroke damage and surgical cancer recurrence.
The Signaling Chain PDE5 Controls
To understand what PDE5 does, you need to follow a short chain of chemical events that happens inside the walls of blood vessels. It starts with nitric oxide (NO), a gas your body produces naturally. Nerve endings and the cells lining blood vessels release NO in response to various signals. Once released, NO drifts into nearby smooth muscle cells and activates an enzyme called soluble guanylate cyclase, which converts a common energy molecule (GTP) into cyclic GMP.1PubMed Central. A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase
Cyclic GMP is the real workhorse here. It activates a protein called PKG, which in turn lowers calcium levels inside the smooth muscle cell.2PubMed. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression Since calcium is what makes muscle cells contract, lowering it causes the muscle to relax. When smooth muscle in a blood vessel wall relaxes, the vessel widens and blood flow increases. This NO → cGMP → PKG → relaxation pathway operates all over the body, in penile tissue, lung arteries, coronary vessels, and peripheral circulation.
PDE5 is the off-switch. It chews up cGMP, converting it back into an inactive form. In tissues where PDE5 is abundant, cGMP levels drop quickly once the initial NO signal fades, and the blood vessel tightens again. The enzyme is especially concentrated in penile smooth muscle, pulmonary arteries, and certain vascular beds, which is why drugs targeting it have their strongest effects in those areas.3International Journal of Impotence Research. Mechanisms of action of PDE5 inhibition in erectile dysfunction
How PDE5 Inhibitors Actually Work
PDE5 inhibitors do not create an erection or dilate a blood vessel on their own. They amplify a signal that is already there. When NO is released and cGMP starts accumulating, the inhibitor blocks PDE5 from breaking that cGMP down. The result is that cGMP sticks around longer and reaches higher concentrations than it normally would, producing a stronger and more sustained relaxation of smooth muscle.3International Journal of Impotence Research. Mechanisms of action of PDE5 inhibition in erectile dysfunction This is why sexual arousal is still necessary for these drugs to work in erectile dysfunction: without arousal, there is no NO release, no cGMP production, and nothing for the inhibitor to amplify.
At the molecular level, the inhibitor sits in the same pocket on the PDE5 enzyme where cGMP would normally bind to be broken down. Researchers have mapped the three-dimensional structures of this catalytic pocket with sildenafil, tadalafil, and vardenafil all docked inside it.4PubMed. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules Each drug molecule has a slightly different shape, which affects how tightly it binds, how long it stays, and whether it also drifts into the active sites of related enzymes elsewhere in the body.
Why There Are Multiple Drugs and How They Differ
Sildenafil, tadalafil, vardenafil, and the newer avanafil all block PDE5, but their pharmacokinetic profiles differ considerably. The most striking difference is duration. Sildenafil and vardenafil last roughly four hours, avanafil about six, while tadalafil lasts around 36 hours, earning it the nickname “the weekend pill.”5PubMed Central. The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction Onset times also vary: sildenafil and vardenafil typically take effect within about 15 to 60 minutes, avanafil can work in as little as 30 minutes, and tadalafil has a wider window of one to 12 hours before intercourse. All four are processed in the liver.6PubMed. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction
These differences matter practically. Tadalafil’s long duration makes it suitable for daily low-dose use, which some people prefer because it removes the need to time a pill before sex. Avanafil’s faster onset appeals to people who want a shorter wait. Sildenafil remains the most widely studied and least expensive option in generic form. Choosing among them often comes down to lifestyle, side-effect tolerance, and whether you are taking other medications that affect liver metabolism.
The Selectivity Problem
Your body has at least 11 different families of phosphodiesterase enzymes, each doing similar work in different tissues. PDE5 inhibitors are designed to target PDE5 specifically, but none of them are perfectly selective. The most clinically relevant overlap is with PDE6, which operates in the retina, and PDE11, found in skeletal muscle and some other tissues. Cross-inhibition of PDE6 is why some people experience a blue tint to their vision or increased light sensitivity after taking sildenafil. Tadalafil has somewhat more activity against PDE11, which may explain occasional reports of back pain and muscle aches with that drug.
Newer experimental compounds aim to sharpen this selectivity. One candidate, TPN729MA, showed over 2,600-fold selectivity for PDE5 over PDE11 and over 10,000-fold selectivity against most other PDE families, while retaining only about 20-fold selectivity over PDE6.7The Journal of Sexual Medicine. The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA Getting PDE6 selectivity higher remains one of the central challenges in designing the next generation of these drugs. Computational approaches now use molecular modeling to predict how candidate molecules will behave across multiple PDE family members before they ever enter a lab.8PubMed Central. Investigation of PDE5/PDE6 and PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
The Nitrate Interaction and Why It Is Dangerous
The single most important safety rule for PDE5 inhibitors is that they must never be combined with nitrate medications. Nitrates, such as nitroglycerin taken for chest pain, work by flooding the body with NO, which in turn ramps up cGMP production. If PDE5 is simultaneously blocked, cGMP accumulates unopposed and blood pressure can plunge dangerously.9PubMed. Phosphodiesterase-5 inhibitors and their hemodynamic effects In a controlled study with healthy men, co-administering sildenafil with sublingual nitroglycerin caused about a four-fold greater drop in systolic blood pressure compared to nitroglycerin alone.10The American Journal of Cardiology. Sildenafil citrate and blood-pressure–lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist That kind of crash can cause fainting, heart attack, or stroke. The interaction applies to all forms of nitrates, whether pills, patches, sprays, or the recreational drug amyl nitrite (“poppers”).
Beyond nitrates, common side effects tend to be mild and related to the same vasodilation mechanism: headache, flushing, nasal congestion, and indigestion. A rarer concern is a sudden, painless loss of vision in one eye caused by reduced blood flow to the optic nerve, a condition called non-arteritic anterior ischemic optic neuropathy. Cases have been reported in sildenafil users, though most visual effects resolve within weeks of stopping the medication.11PubMed Central. Non-Arteritic Anterior Ischemic Optic Neuropathy Associated With the Use of Phosphodiesterase Type 5 Inhibitors: A Literature Review
Beyond Erections: Pulmonary Hypertension
Sildenafil’s path from failed angina drug to erectile dysfunction treatment to approved pulmonary hypertension therapy is one of the more famous stories in pharmacology. It was originally developed in the late 1980s as a heart medication. When early trials showed disappointing results for angina but an unexpected side effect in male participants, the drug was redirected.12PubMed Central. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond Later, researchers recognized that the same cGMP-mediated vasodilation could relieve the dangerously high pressures in the lung arteries that characterize pulmonary arterial hypertension. In animal models, sildenafil reduced pulmonary artery pressure by up to 90 percent when given before the onset of hypoxia-induced hypertension, and by about 30 percent when started after the disease was already established.13PubMed. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension A Cochrane review confirmed that PDE5 inhibitors increase vasodilation and slow abnormal cell growth in pulmonary arteries.14PubMed Central. Phosphodiesterase 5 inhibitors for pulmonary hypertension Sildenafil is now marketed under the brand name Revatio specifically for this indication, at different doses than those used for erectile dysfunction.
Other Conditions Where PDE5 Inhibitors Show Up
Because cGMP-driven smooth muscle relaxation affects blood vessels throughout the body, PDE5 inhibitors have been tried in a number of conditions involving poor blood flow. One of the better-studied off-label uses is Raynaud’s phenomenon, where blood vessels in the fingers and toes spasm in response to cold or stress, turning them white and painful. A meta-analysis of six randomized trials found that PDE5 inhibitors reduced the daily frequency of attacks and shortened their duration by roughly 15 minutes per episode.15PubMed. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials The drugs have become a common treatment among specialists who manage scleroderma patients with Raynaud’s and digital ulcers.16PubMed Central. PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials
In cardiology, animal and early human studies have shown that PDE5 inhibitors can improve the heart’s pumping ability in certain types of heart failure, reduce the thickening of heart muscle caused by chronic pressure overload, and limit the size of damage after a heart attack.17PubMed Central. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? In one experimental model, sildenafil halted the progressive enlargement and stiffening of an already-damaged heart and restored more normal calcium handling in heart muscle cells.18Journal of the American College of Cardiology. Sildenafil Stops Progressive Chamber, Cellular, and Molecular Remodeling and Improves Calcium Handling and Function in Hearts With Pre-Existing Advanced Hypertrophy Caused by Pressure Overload These cardiac applications are still largely investigational, but the consistency of the signal across studies is notable.
When PDE5 Inhibitors Do Not Work
Roughly a quarter to a third of men prescribed PDE5 inhibitors for erectile dysfunction do not get satisfactory results. The reasons vary. Some failures are genuinely pharmacological: severe nerve damage from diabetes or prostate surgery may mean there simply is not enough NO being released for the drug to amplify. Others are logistical. A common mistake is taking the drug with a heavy meal, which slows absorption of sildenafil and vardenafil substantially (tadalafil is less affected by food). Some men give up after one or two tries without realizing that the drugs may take several attempts to produce the best results.19PubMed Central. Treatment Strategy for Non-Responders to PDE5 Inhibitors
A less well-known issue is tachyphylaxis, where the tissue gradually becomes less responsive to the drug even though the dose stays the same. This can happen because of changes in the underlying vascular health or because the body upregulates PDE5 production in response to chronic inhibition.20PubMed. The management of phosphodiesterase-5 (PDE5) inhibitor failure In laboratory settings, arteries exposed to sustained changes in blood flow actually increase their PDE5 levels, making them less sensitive to the normal NO-cGMP relaxation signal.21Journal of Molecular and Cellular Cardiology. Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow For people whose erectile dysfunction has a strong psychological component, the pill may work physically but fail to address the anxiety or relationship issues driving the problem.
The Enzyme’s Built-In Feedback Loop
PDE5 has an interesting trick that most descriptions leave out. Besides its catalytic site, where it breaks down cGMP, the enzyme has two additional binding pockets called allosteric sites. When cGMP levels rise, some of that cGMP binds to these allosteric sites. That binding does not speed up cGMP breakdown directly. Instead, it makes the enzyme easier to activate through phosphorylation by PKG, the very same protein that cGMP activates downstream.22PubMed Central. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation Once phosphorylated, PDE5 binds cGMP even more tightly at those allosteric sites, effectively sequestering cGMP away from where it can do its signaling work.23PubMed. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum
This creates a negative feedback loop. Rising cGMP primes PDE5 to soak up more cGMP, pulling the brakes on the very signal that activated the enzyme in the first place. It is an elegant self-limiting system, and it partly explains why PDE5 inhibitors, despite dramatically boosting cGMP, do not usually cause runaway effects. The enzyme is constantly adjusting its own sensitivity to match the signaling environment.
Emerging Research in the Brain and Immune System
Some of the most intriguing recent work on PDE5 inhibitors has nothing to do with blood vessels in the usual sense. In preclinical stroke research, PDE5 inhibitors reduced neuronal death, dampened inflammation, and promoted the growth of new blood vessels in damaged brain tissue, all through the same NO-cGMP-PKG pathway that operates elsewhere in the body.24Cellular Signalling. Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies A recent meta-analysis in humans found that PDE5 inhibitors modestly increased blood flow to brain regions affected by small-vessel disease, though the overall effect on blood flow velocity did not reach statistical significance.25Frontiers in Neurology. Phosphodiesterase-5 inhibitors for cerebral small vessel disease-related ischemic stroke and cognitive decline: systematic review and meta-analysis Whether that blood flow improvement translates into preserved cognitive function is still an open question, but several clinical trials are underway.
In oncology, the interest is not in blood flow but in immune surveillance. After major surgery, the body’s immune defenses are temporarily suppressed, which may give residual cancer cells a window to establish metastases. In animal models, perioperative sildenafil reduced the activity of immune-suppressing cells that surge after surgery, restoring the cancer-killing ability of natural killer cells and reducing subsequent metastatic disease.26PubMed Central. Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity These are early-stage findings and no one should take sildenafil hoping to prevent cancer, but the mechanism is plausible and clinical trials are exploring it.
High Altitude and the Limits of Vasodilation
One place where PDE5 inhibitors have not lived up to expectations is in preventing high-altitude pulmonary edema, a dangerous fluid buildup in the lungs triggered by the low oxygen levels at extreme elevation. Because the condition involves excessive constriction of pulmonary blood vessels, and because sildenafil effectively relaxes those vessels in pulmonary hypertension patients, the logic for using it prophylactically at altitude seemed sound. However, a randomized trial in healthy lowlanders ascending to about 5,200 meters found no significant difference in pulmonary artery pressure between sildenafil and placebo groups. Worse, altitude sickness symptoms were actually more severe on the second day in the sildenafil group.27PubMed. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial The researchers concluded that routine prophylactic use at high altitude in healthy people is not supported. This result is a useful reminder that a drug can work perfectly well on one vascular bed in one disease context and fail in what looks like a closely related scenario. The biology at altitude involves mechanisms beyond simple vasoconstriction, and PDE5 inhibition alone is not enough to override them.
The Calcium Connection in More Detail
The downstream step where PDE5 inhibitors ultimately exert their effect is calcium regulation. In smooth muscle, contraction is driven by a rise in intracellular calcium. The PKG activated by cGMP reduces calcium levels through multiple routes: it promotes calcium pumping back into internal storage compartments, reduces calcium influx from outside the cell, and alters the sensitivity of the contractile machinery itself. One key mechanism involves a protein called IRAG, which works with PKG to suppress calcium release from internal stores. When IRAG was experimentally silenced in human colon smooth muscle cells, the NO-cGMP pathway could no longer inhibit calcium spikes, confirming that IRAG is a required link in the chain.28PubMed. InsP3R-associated cGMP kinase substrate (IRAG) is essential for nitric oxide-induced inhibition of calcium signaling in human colonic smooth muscle This matters clinically because it explains why PDE5 inhibitors work best in tissues where this particular signaling chain is intact. Nerve damage, endothelial dysfunction, or deficiencies in any of these downstream proteins can blunt the drug’s effect regardless of how completely PDE5 itself is blocked.